Quest Diagnostics Stock Fair Value – Quest Diagnostics Shares Slip 0.41% Despite Bullish Market Session
July 4, 2023
☀️Trending News
On Friday, Quest Diagnostics ($NYSE:DGX) Inc. saw its stock fall 0.41% to $140.56, despite the stock market experiencing overall positive gains. The company serves patients, physicians, hospitals, health plans, and employers with a range of medical tests and services.
Analysis – Quest Diagnostics Stock Fair Value
At GoodWhale, we have completed an analysis of QUEST DIAGNOSTICS‘s financials and our proprietary Valuation Line has calculated the fair value of a QUEST DIAGNOSTICS share to be around $148.8. However, currently the stock is trading at $139.2, which is fair, but slightly undervalued by 6.5%. We recommend that investors take advantage of this opportunity and invest in QUEST DIAGNOSTICS now, as the stock is likely to appreciate in value soon. More…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Quest Diagnostics. More…
| Total Revenues | Net Income | Net Margin |
| 9.6k | 789 | 8.3% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Quest Diagnostics. More…
| Operations | Investing | Financing |
| 1.33k | -532 | -1.34k |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Quest Diagnostics. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 12.79k | 6.63k | 54.02 |
Key Ratios Snapshot
Some of the financial key ratios for Quest Diagnostics are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 7.8% | 1.8% | 12.6% |
| FCF Margin | ROE | ROA |
| 9.0% | 12.6% | 5.9% |
Peers
The competition among Quest Diagnostics Inc, Dr Lalchandani Labs Ltd, NeoGenomics Inc, and Shanghai Labway Clinical Laboratory Co Ltd is fierce. All four companies are vying for a piece of the pie in the diagnostic testing market. While Quest Diagnostics Inc is the largest of the four companies, the other three are not far behind. Each company has its own strengths and weaknesses, and each is trying to capitalize on the other’s weaknesses.
– Dr Lalchandani Labs Ltd ($BSE:541299)
Lalchandani Labs Ltd is a pharmaceutical company that manufactures and markets a range of prescription and over-the-counter drugs. The company has a market cap of 141.91M as of 2022 and a return on equity of 12.87%. The company’s products are sold in over 50 countries and its products are used by millions of people around the world. The company has a strong research and development team that is constantly innovating and developing new products. The company’s products are backed by a strong clinical research and manufacturing infrastructure.
– NeoGenomics Inc ($NASDAQ:NEO)
NeoGenomics Inc is a leading provider of cancer genetic testing and information services. The company has a market cap of 934.66M as of 2022 and a Return on Equity of -3.79%. NeoGenomics provides a full range of services including DNA sequencing, gene expression profiling, FISH testing, and Flow Cytometry. The company also offers a wide array of diagnostic tests including next generation sequencing, immunohistochemistry, and in situ hybridization. NeoGenomics serves a global customer base of oncologists, pathologists, pharmaceutical companies, and academic research centers.
– Shanghai Labway Clinical Laboratory Co Ltd ($SZSE:301060)
Shanghai Labway Clinical Laboratory Co Ltd is a clinical laboratory located in Shanghai, China. The company provides a range of laboratory services, including medical testing, tissue culture, and genetic testing. The company has a market cap of 9.31B as of 2022 and a Return on Equity of 27.69%. The company’s strong market position and financial performance are due to its focus on quality and customer service. The company has a well-established reputation in the industry and is known for its accurate and reliable results.
Summary
Quest Diagnostics Inc., a major provider of diagnostic testing and information services, has seen its share price dip 0.41% to $140.56 on Friday, despite the stock market’s overall positive performance. Analysts cite the company’s recent quarterly earnings report as a primary factor in this slight decrease, citing weaker-than-expected revenue growth and higher costs.
In addition, concern over the impact of the coronavirus pandemic on the medical services sector continues to weigh on investors. Despite the short-term hiccup, analysts remain bullish on the stock long-term, given Quest Diagnostics’ strong reputation, robust financials, and operational capabilities. The company’s expansive network of regional offices and laboratories, along with its expanding range of services, position it well for continued success. Investors are advised to keep an eye on the stock and consider buying on any further dips.
